News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

XVIVO Perfusion AB Release: NOVEL Trial Recruitment of Patients Complete, FDA Has Decided That an Expert Panel Meeting Will be Held Q1 of 2014


9/20/2013 9:30:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

All 42 planned patients in Xvivo Perfusion’s American clinical trial using STEEN Solution™ have received transplants. In the ongoing follow-up good clinical results have been obtained. The patients are being followed up over a period of one year. During a meeting with the FDA it was decided that the expert panel meeting preceding the decision on HDE registration (Humanitarian Device Exemption) will be held within four to five months.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES